SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Lupin recalls one batch of BP tablets from the US market

09 Aug 2011 Evaluate

Lupin is recalling one batch of high blood pressure (BP) tablets --losartan potassium-- from the US market. The drugs with the expiry in July next year are being recalled after they exceeded the permissible impurity level.

Further, as per the US Food and Drug Administration (FDA) enforcement report, the product did not meet specification for impurities at the 9-month stability station. Further, the recall falls under the FDA's Class II category which means that the use of the drug may cause temporary or medically reversible adverse health consequences, but unlikely to have serious adverse health consequences.

The company informed the authorities about the deficiency of the drug made at the company’s Goa facility in the last month and since then the recall is going on. In total there are over 34 thousands bottles in the market.

In June, the company also recalled about 5,000 bottles of BP drug perindopril erbumine tablets from the US market because the drug was subpotent. The drug was also made at the Goa plant. Additionally, in April, the company voluntary recalled a batch of its hypertension drug Lisinopril because of adulterated presence of foreign tablets.

Lupin Share Price

2324.25 -2.25 (-0.10%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×